In light of the fact that the prevalence of obesity and CRC is increasing in an alarming rate, a more detailed studies identifying the roles and mechanisms of action of NLRP3 as well as the clinical development of molecules to selectively antagonize the NLRP3 inflammasome may lead to a better understanding of the pathogenesis of obesity-associated comorbidities as well as to the develop of innovative precision medicine approaches for the management of obesity and its complications (215, 216). The gene discussed is NLRP3; the disease is obesity disorder.